<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00892346</url>
  </required_header>
  <id_info>
    <org_study_id>MHOPES-myeloma09</org_study_id>
    <nct_id>NCT00892346</nct_id>
  </id_info>
  <brief_title>Single Autologous Stem Cell Transplantation Followed by Maintenance Therapy as Front-line Treatment for Myeloma</brief_title>
  <official_title>Phase III Study of Single Autologous Stem Cell Transplantation Followed by Maintenance Therapy as Front-line Treatment for Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical trial is to evaluate the efficacy of single autologous hematopoietic stem cell
      transplantation with standard conditioning of melphalan 200 mg/m2 followed by thalidomide
      maintenance in patients with newly-diagnosed myeloma after receiving 4-6 cycles of induction
      chemotherapy consisting of vincristin,adriamycin and dexamethasone (VAD) or
      thalidomide/dexamethasone between 18 to 65 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label clinical trial to evaluate the efficacy of single autologous
      hematopoietic stem cell transplantation in newly diagnosed multiple myeloma patients. All
      patients will receive 4-6 cycles of induction therapy which includes VAD chemotherapy
      (vincristin, adriamycin and dexamethasone) or thalidomide/dexamethasone. After peripheral
      hematopoietic stem cell mobilization and apheresis, patients will receive a standard
      conditioning with melphalan 200mg/m2 followed by thalidomide maintenance therapy at 100-200mg
      orally daily starting from D+60 till disease progression or untolerable toxicity.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    No avaliability of melphlan in mainland China
  </why_stopped>
  <start_date>May 2009</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>response rate: CR/nCR/VGPR</measure>
    <time_frame>6 months after auto-PBSCT</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicity</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Single ASCT with Thalidomide maintenance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ASCT followed by Thalidomide maintenance:
patients recieved 4-6 cycles of standard VAD chemotherapy or Thalidomide/dexamethasone as induction therapy
CTX+G-SCF mobilization to collecetd PBSC
Patiens recieved Mel 200 as conditioning followed by Thalidomide 100mg maintenance</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Single ASCT with Thalidomide maintenance</intervention_name>
    <description>Single ASCT with Thalidomide maintenance:
Single Autologous Stem Cell Transplantation: conditioning with Melphalan 200mg/m2 (iv)
Thalidomide maintenance: starting from D60 after transplantation at 100-200mg daily (Oral)</description>
    <arm_group_label>Single ASCT with Thalidomide maintenance</arm_group_label>
    <other_name>multiple myeloma</other_name>
    <other_name>melphalan</other_name>
    <other_name>thalidomie</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Man or woman between age 18-65 with newly diagnosed Multiple Myeloma for whom stem
             cell transplantation is considered appropriate

          -  Measurable serum and/or urinary paraprotein

          -  European Cooperative Oncology Group performance status 0-3

          -  Serum bilirubin &lt; 1.5x the upper limit of normal (ULN)

          -  Serum alanine transaminase (ALT)/aspartate transaminase values &lt; 2.5 x ULN

          -  Subjects (or their legally acceptable representatives) must signed an informed consent
             document indicating that they understanding the purpose of and procedures required for
             the study and are willing to participate in the study

        Exclusion criteria:

          -  Woman of child bearing potential

          -  Non-secretory MM

          -  Serum creatinine &gt; 400 Micromol/l after initial resuscitation

          -  patients with previous Grade 2-4 peripheral neuropathy

          -  Uncontrolled diabetes (if receiving antidiabetic agents, subjects must be on a stable
             dose for at least 3 months before first dose of study drug

          -  Uncontrolled or severe cardiovascular disease including myocardial infarction within 6
             months of enrollment, uncontrolled angina, clinically significant pericardial disease,
             or III-IV heart failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiong HU, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rui Jin Hospital, Shanghai JiaoTong University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rui Jin Hospital, Shanghai JiaoTong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Chang JE, Juckett MB, Callander NS, Kahl BS, Gangnon RE, Mitchell TL, Longo WL. Thalidomide maintenance following high-dose melphalan with autologous stem cell support in myeloma. Clin Lymphoma Myeloma. 2008 Jun;8(3):153-8. doi: 10.3816/CLM.2008.n.018.</citation>
    <PMID>18650178</PMID>
  </reference>
  <reference>
    <citation>Abdelkefi A, Ladeb S, Torjman L, Othman TB, Lakhal A, Romdhane NB, Omri HE, Elloumi M, Belaaj H, Jeddi R, Aissaou誰 L, Ksouri H, Hassen AB, Msadek F, Saad A, Hsa誰ri M, Boukef K, Amouri A, Louzir H, Dellagi K, Abdeladhim AB; Tunisian Multiple Myeloma Study Group. Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. Blood. 2008 Feb 15;111(4):1805-10. Epub 2007 Sep 17. Retraction in: Abdelkefi A, Ladeb S, Torjman L, Ben Othman T, Lakhal A, Ben Romdhane N, Elloumi M, Jeddi R, Aissaou誰 L, Ben Hassen A, Msadek F, Saad A, Hsa誰ri M. Blood. 2009 Jun 11;113(24):6265.</citation>
    <PMID>17875806</PMID>
  </reference>
  <reference>
    <citation>Harousseau JL, Moreau P. Evolving role of stem cell transplantation in multiple myeloma. Clin Lymphoma Myeloma. 2005 Sep;6(2):89-95. Review.</citation>
    <PMID>16231846</PMID>
  </reference>
  <reference>
    <citation>Spencer A, Prince HM, Roberts AW, Prosser IW, Bradstock KF, Coyle L, Gill DS, Horvath N, Reynolds J, Kennedy N. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol. 2009 Apr 10;27(11):1788-93. doi: 10.1200/JCO.2008.18.8573. Epub 2009 Mar 9.</citation>
    <PMID>19273705</PMID>
  </reference>
  <reference>
    <citation>Kumar A, Kharfan-Dabaja MA, Glasmacher A, Djulbegovic B. Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. J Natl Cancer Inst. 2009 Jan 21;101(2):100-6. doi: 10.1093/jnci/djn439. Epub 2009 Jan 13. Review.</citation>
    <PMID>19141779</PMID>
  </reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2009</study_first_submitted>
  <study_first_submitted_qc>May 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2009</study_first_posted>
  <last_update_submitted>May 9, 2016</last_update_submitted>
  <last_update_submitted_qc>May 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Jiong HU</investigator_full_name>
    <investigator_title>Head, Blood and Marrow Transplantation Center, Rui Jin Hospital</investigator_title>
  </responsible_party>
  <keyword>autologous hematopoietic stem cell transplantation</keyword>
  <keyword>maintenance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

